MedTrace Logo

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

NCT06686615 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-05-08

No results posted yet for this study

Summary

Data on the real-world use and effectiveness and safety of bempedoic acid combined with both a statin and ezetimibe in clinical practice is limited. There is an increased focus on using combination therapy to lower LDL-C.

Conditions

  • Primary Hypercholesterolemiia
  • Mixed Dyslipidemia

Interventions

DRUG

Bempedoic acid

No drug was administered in this observational study.

DRUG

Ezetimibe

No drug was administered in this observational study.

DRUG

Rosuvastatin

No drug was administered in this observational study.

DRUG

Atorvastatin

No drug was administered in this observational study.

Sponsors & Collaborators

  • Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-12
Primary Completion
2027-07-31
Completion
2028-01-31

Countries

  • Austria
  • Belgium
  • Germany
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06686615 on ClinicalTrials.gov